Evidence map›Paper›PMID 42242224›Full record

ArticleCell2026

Plasma signals of lung tumor promotion for molecular cancer prevention.

Tej Pandya, Maria Zagorulya, Michelle M Leung, Marcellus Augustine, Lydia Y Liu, Aino-Maija Leppä, Ulysse Baruchel, Sin Wi Ng, Tamara Klockner, Miriam Mugabo and 77 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Sex-specific associations of the bilirubin-to-albumin ratio with lung cancer risk: evidence from Cox regression and causal survival forest analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

87 authors.

Tej PandyaCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; UKRI UCL Centre for Doctoral Training in AI-enabled Healthcare Systems, University College London, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Maria ZagorulyaCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Michelle M LeungCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK; Cancer Genome Evolution Research Group, University College London Cancer Institute, London, UK.
Marcellus AugustineCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK; Division of Medicine, University College London, London, UK.
Lydia Y LiuCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Aino-Maija LeppäCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Ulysse BaruchelCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Sin Wi NgWalter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
Tamara KlocknerCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Miriam MugaboCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Anthony J GriffenDepartment of Cell Biology, Albert Einstein College of Medicine, Montefiore Health System, Bronx, New York, NY, USA; Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, New York, NY, USA.
Oleg BlyussCentre for Cancer Screening, Prevention and Early Diagnosis, Wolfson Institute of Population Health, Queen Mary University of London, London, UK; Department of Paediatrics and Paediatric Infectious Diseases, Institute of Child's Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
Chrysante S IliakisImmunoregulation Laboratory, The Francis Crick Institute, London, UK.
Amalie GrenovAutoimmunity Laboratory, The Francis Crick Institute, London, UK.
Kerstin HaaseCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK; Cancer Metastasis Laboratory, University College London Cancer Institute, London, UK.
David C MullerDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
Ka Hung ChanClinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK; Oxford Global Health, University of Oxford, Oxford, UK.
Jincheng WuNovartis, Cambridge, MA, USA.
Vernon A BurkDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Neil WrightClinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Alix Le MaroisTumour Cell Biology Laboratory, The Francis Crick Institute, London, UK.
Ekaterina PazukhinaCentre for Cancer Screening, Prevention and Early Diagnosis, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
Sophia WardCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK; Genomics Science Technology Platform, The Francis Crick Institute, London, UK.
Hubert SlawinskiGenomics Science Technology Platform, The Francis Crick Institute, London, UK.
Marc PelletierNovartis, Cambridge, MA, USA.
Cian MurphyCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Matthew D ParkMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Thomas SnoeksImaging Research Facility, The Francis Crick Institute, London, UK.
Alejandro Suarez-BonnetDepartment of Pathobiology & Population Sciences, The Royal Veterinary College, London, UK; Experimental Histopathology, The Francis Crick Institute, London, UK.
Simon L PriestnallDepartment of Pathobiology & Population Sciences, The Royal Veterinary College, London, UK; Experimental Histopathology, The Francis Crick Institute, London, UK.
Alexandros ChardasDepartment of Pathobiology & Population Sciences, The Royal Veterinary College, London, UK.
Charlotte GriecoCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Ami ArcherCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Alpkaan CelikCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Alejandro Jimenez-SanchezComputational and Systems Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Rachel ScottCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK; Cancer Metastasis Laboratory, University College London Cancer Institute, London, UK.
Hana ZahedEarly Detection, Prevention and Infections Branch (EPR), International Agency for Research on Cancer (IARC/WHO), Lyon, France.
Léa MontégutMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Rafael MezaDepartment of Population Health Sciences, British Columbia Cancer Research Institute, Vancouver, BC, Canada.
Clinton H DurneyDepartment of Population Health Sciences, British Columbia Cancer Research Institute, Vancouver, BC, Canada.
Stephen LamDepartment of Basic and Translational Research, British Columbia Cancer Research Institute, Vancouver, BC, Canada.
Takahiro KarasakiCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK; Department of Thoracic Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Roel C H VermeulenInstitute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, the Netherlands.
Huilei XuNovartis Biomedical Research, Cambridge, MA, USA.
Pablo Serrano-FernandezNovartis Pharmaceuticals, Basel, Switzerland.
Tatjana Crnogorac-JurcevicCentre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London, UK.
Usha MenonUCL Innovative Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK.
Sophia ApostolidouUCL Innovative Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK.
Alexey ZaikinDepartment of Mathematics and Institute for Women's Health, University College London, London, UK; Centre for Cognition and Decision making, Institute for Cognitive Neuroscience, HSE University, Moscow, Russia.
Richard GunuDepartment of Women's Cancer, Institute for Women's Health, University College London, London, UK.
Harry J WhitwellNational Phenome Centre and Imperial Clinical Phenotyping Centre, Department of Metabolism, Digestion and Reproduction, IRDB, Imperial College London, London, UK; Section of Bioanalytical Chemistry, Burlington Danes Building, Division of Systems Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
Zhe HuangNuffield Department of Population Health, University of Oxford, Oxford, UK.
Zonglun LiCentre for Cancer Screening, Prevention and Early Diagnosis, Wolfson Institute of Population Health, Queen Mary University of London, London, UK; Department of Women's Cancer, Institute for Women's Health, University College London, London, UK.
Xin HuDepartment of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Bo ZhuDepartment of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Liming LiDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, China; Peking University Center for Public Health and Epidemic Preparedness & Response, Beijing, China; Key Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of Education, Beijing, China.
María-Dolores ChirlaqueDepartment of Epidemiology, Regional Health Council, Murcia University, Murcia, Spain; CIBER in Epidemiology and Public Health (CIBERESP), Madrid, Spain; Biomedical Research Institute of Murcia Pascual Parrilla-IMIB, 30120 Murcia, Spain.
Marcela GuevaraCIBER in Epidemiology and Public Health (CIBERESP), Madrid, Spain; Instituto de Salud Pública y Laboral de Navarra, 31003 Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), 31008 Pamplona, Spain.
P Martijn KolijnInstitute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, the Netherlands.
Aghiles GuenounEarly Detection, Prevention and Infections Branch (EPR), International Agency for Research on Cancer (IARC/WHO), Lyon, France.
Neeloffer MookherjeeMax Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada.
Mattias JohanssonEarly Detection, Prevention and Infections Branch (EPR), International Agency for Research on Cancer (IARC/WHO), Lyon, France.
Ziqiao WangDepartment of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Nilanjan ChatterjeeDepartment of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Chao-Hua ChiuDepartment of Internal Medicine, Taipei Medical University Hospital, Taipei Medical University, Taipei, Taiwan.
Zhengming ChenClinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Dana Pe'erComputational and Systems Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Howard Hughes Medical Institute, New York, NY, USA.
Erik SahaiTumour Cell Biology Laboratory, The Francis Crick Institute, London, UK.
Saskia FreytagWalter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia; Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia.
Andreas WackImmunoregulation Laboratory, The Francis Crick Institute, London, UK.
Marc J GunterDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK; Cancer Epidemiology and Prevention Research Unit, School of Public Health, Imperial College London, London, UK.
Miriam MeradMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Jianjun ZhangDepartment of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Christopher CarlstenAir Pollution Exposure Laboratory, Division of Respiratory Medicine, Department of Medicine, Vancouver Coastal Health Research Institute, The University of British Columbia, Vancouver, BC, Canada.
Pan-Chyr YangNational Taiwan University YongLin Institute of Health, National Taiwan University, Taipei 106, Taiwan; Department of Internal Medicine, National Taiwan University College of Medicine, Taipei 100, Taiwan; Institute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan.
Hsuan-Yu ChenInstitute of Statistical Science, Academia Sinica, Taipei 115, Taiwan.
Elizabeth A PlatzDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Lindsay M LaFaveDepartment of Cell Biology, Albert Einstein College of Medicine, Montefiore Health System, Bronx, New York, NY, USA; Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, New York, NY, USA.
Karl Smith-ByrneCancer Epidemiology Unit, University of Oxford, Oxford OX3 7LF UK.
Mariam Jamal-HanjaniCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK; Cancer Metastasis Laboratory, University College London Cancer Institute, London, UK; Department of Oncology, University College London Hospitals, London, UK.
Kevin LitchfieldCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Nuno R NeneCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Nicholas McGranahanCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK; Cancer Genome Evolution Research Group, University College London Cancer Institute, London, UK.
Eva GrönroosCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
William HillCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK. Electronic address: william.hill@cruk.manchester.ac.uk.
Clare E WeedenCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia; Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia. Electronic address: weeden.c@wehi.edu.au.
Charles SwantonCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK; Department of Oncology, University College London Hospitals, London, UK. Electronic address: charles.swanton@crick.ac.uk.

Funding

THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - COORDINATING CENTER - TASK AREA B.2 AND B.375N92022D00001 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI COUPER, DAVID · 2022 to 2025
$13.7M
THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - FIELD CENTER - TASK ORDER 01, TASK AREA A75N92022D00003 · NHLBI · UNIVERSITY OF MINNESOTA · PI LUTSEY, PAMELA L. · 2022 to 2025
$5.1M
THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - FIELD CENTER - TASK ORDER 01, TASK AREA A75N92022D00005 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI WAGENKNECHT, LYNNE · 2022 to 2025
$5.0M
THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - FIELD CENTER - TASK ORDER 01, TASK AREA A75N92022D00004 · NHLBI · UNIVERSITY OF MISSISSIPPI MED CTR · PI WINDHAM, BEVERLY GWEN · 2022 to 2025
$4.8M
THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - FIELD CENTER - TASK ORDER 01, TASK AREA A75N92022D00002 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI CORESH, JOSEF · 2022 to 2025
$4.7M
Enhancing ARIC Infrastructure to Yield a New Cancer Epidemiology CohortU01CA164975 · NCI · JOHNS HOPKINS UNIVERSITY · PI PLATZ, ELIZABETH A. · 2012 to 2018
$3.8M
Profiling Cardiovascular Events and Biomarkers in the Very Old to Improve Personalized Approaches for the Prevention of Cardiac and Vascular DiseaseR01HL134320 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI BALLANTYNE, CHRISTIE MITCHELL, SELVIN, ELIZABETH · 2016 to 2019
$3.1M
Training Program in Cellular and Molecular Biology and GeneticsT32GM145438 · NIGMS · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI CHARLES C QUERY · 2023 to 2026
$2.4M
Biomechanical regulation of chromatin states in lung cancerF31CA295001 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI Anthony Griffen · 2025 to 2026
$100k
NCI NIH HHS F31 CA295001NCI NIH HHS U01 CA164975NHLBI NIH HHS 75N92022D00001NHLBI NIH HHS 75N92022D00002NHLBI NIH HHS 75N92022D00003NHLBI NIH HHS 75N92022D00004NHLBI NIH HHS 75N92022D00005NHLBI NIH HHS R01 HL134320NIGMS NIH HHS T32 GM145438Wellcome Trust CC2041
6 · The paper itself

Abstract

Predicting lung cancer risk would enhance prevention trials. Although the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial demonstrated reduced lung cancer incidence with interleukin (IL)-1β inhibition, the high number needed to treat (NNT) to prevent lung cancer limits its use in unselected populations. Using machine learning, we identified a 14-protein plasma signature predicting lung cancer more than 5 years before diagnosis. The signature, validated across eight cohorts, was elevated in current smokers and individuals exposed to particulate matter (PM) and linked to lung myeloid and alveolar cells. In epidermal growth factor receptor (EGFR)-driven lung adenocarcinoma, diverse epithelial lineages converged on a keratin8

Indexed as

Lung NeoplasmsAdenocarcinoma of LungAnimalsErbB ReceptorsFemaleHumansInterleukin-1betaMaleErbB ReceptorsInterleukin-1betacancer cell of origincancer preventionlung adenocarcinomalung cancer initiationlung cancer preventionlung cancer riskplasma proteomicssecretory alveolar nichetumor promotion

Identifiers

PMID42242224
PMCPMC13573819

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.